CIK 0001048477
- Large accelerated filer
BIOMARIN PHARMACEUTICAL INC
Sign in to watch- Ticker
- BMRN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 680397820
- Phone
- +1 415-506-6700
- Business address
- 105 DIGITAL DRIVE, NOVATO, CA, 94949
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,466,459
- in 2 filings
Net −$1,466,459. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-03-10 | BIENAIME JEAN JACQUES Chief Executive Officer | Exercise or conversion | +15,000 | $37.46 | $562K | 353,569 |
| 2022-03-10 | BIENAIME JEAN JACQUES Chief Executive Officer | Sale | −15,000 | $77.57 | $1.2M | 338,569 |
| 2022-03-10 | BIENAIME JEAN JACQUES Chief Executive Officer | Exercise or conversion · Stock Option (Right to buy Common Stock) | −15,000 | 100,000 | ||
| 2022-03-08 | BIENAIME JEAN JACQUES Chief Executive Officer | Grant or award | +34,780 | 338,569 | ||
| 2022-03-08 | FUCHS HENRY J President, Worldwide R&D | Grant or award | +12,840 | 119,323 | ||
| 2022-03-08 | Davis George Eric EVP, General Counsel | Grant or award | +9,370 | 67,960 | ||
| 2022-03-08 | Ajer Jeffrey Robert EVP, Chief Commercial Officer | Grant or award | +9,370 | 65,223 | ||
| 2022-02-28 | Slamon Dennis Director | Sale | −5,815 | $78.33 | $455K | 22,220 |
| 2022-02-28 | Slamon Dennis Director | Sale | −45 | $78.34 | $4K | 22,175 |
| 2022-02-28 | Slamon Dennis Director | Sale | −214 | $78.35 | $17K | 21,961 |
| 2022-02-28 | Slamon Dennis Director | Sale | −100 | $78.35 | $8K | 21,861 |
| 2022-02-28 | Slamon Dennis Director | Sale | −122 | $78.36 | $10K | 21,739 |
| 2022-02-28 | Slamon Dennis Director | Sale | −100 | $78.37 | $8K | 21,639 |
| 2022-02-25 | HERON ELAINE J Director | Exercise or conversion | +8,500 | $37.46 | $318K | 80,588 |
| 2022-02-25 | HERON ELAINE J Director | Exercise or conversion · Stock Option (Right to buy Common Stock) | −8,500 | 0 | ||
| 2022-02-03 | Mueller Brian EVP, Chief Financial Officer | Shares withheld for taxes | −1,072 | $87.77 | $94K | 29,709 |
| 2022-01-14 | LAWLIS V BRYAN Director | Exercise or conversion | +4,250 | $37.46 | $159K | 28,220 |
| 2022-01-14 | LAWLIS V BRYAN Director | Sale | −4,250 | $87.61 | $372K | 23,970 |
| 2022-01-14 | LAWLIS V BRYAN Director | Exercise or conversion · Stock Option (Right to buy Common Stock) | −4,250 | 4,250 | ||
| 2022-01-13 | BIENAIME JEAN JACQUES Chief Executive Officer | Exercise or conversion | +5,000 | $37.46 | $187K | 308,789 |
Page 26 of 36 · 707 trades